Prostate cancer: was the treatment guideline-concordant?

Prostate cancer is unusual in both directions. Low-risk disease is one of the most overtreated conditions in oncology, and advanced disease is one of the most undertreated. The clinical practice guidelines address both, which makes a concordance check useful at either end.

The decisions that matter

• Risk stratification. PSA, the Gleason score (grade group), and stage combine into a risk group, and the risk group drives everything after it. A record that never establishes the risk group is hard to defend.
• Active surveillance for low-risk disease. For low-risk cancer, the guidelines put active surveillance ahead of immediate surgery or radiation for most men. Going straight to prostatectomy, with its real rates of incontinence and impotence, without surveillance ever being discussed is a guideline problem, not just a style choice.
• Germline and somatic testing. Metastatic and high-risk disease should prompt genetic testing, including BRCA. The result has treatment consequences later on.
• Androgen deprivation for metastatic disease. ADT is the backbone of treatment once the cancer has spread.
• Intensification beyond ADT alone. For metastatic hormone-sensitive disease, ADT by itself is no longer the standard. The guidelines call for adding a drug such as abiraterone, enzalutamide, apalutamide, or docetaxel. Men left on ADT alone for years are being treated to an outdated standard.
• PARP inhibitors for BRCA-mutated resistant disease. When castration-resistant disease carries a BRCA or related mutation, the guidelines list PARP inhibitors such as olaparib. This is exactly why the genetic testing above matters.

What a deviation looks like

A man with low-risk disease rushed to surgery with no record of surveillance being offered. Metastatic disease managed with ADT alone year after year. A known BRCA mutation in castration-resistant disease with no PARP inhibitor ever mentioned. Each finding cites its guideline page, so the pattern is easy for a professional to verify.